Illumina offers a broad portfolio of cancer-focused next-generation sequencing (NGS) panels across multiple application areas. These products have been optimized with clinical cancer research in mind. Achieve sequence-ready libraries from as little as 1 ng of high-quality input or 10 ng formalin-fixed paraffin-embedded (FFPE) sample using efficient, optimized assays and integrated sequencing and bioinformatics. Our comprehensive offering includes both fixed panels and custom options.
NGS cancer panels
Explore fixed and custom research panels targeting known variants for cancer-related genes.
Targeted panels tailored for cancer research
Featured products
TruSight RNA Pan-Cancer Panel
Targeting 1385 cancer genes for gene expression, variant, and fusion detection studies in many RNA sample types including blood, bone marrow, and formalin-fixed, paraffin-embedded (FFPE) tissue.
View productFeatured products
TruSight Oncology 500
Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI, and HRD) from FFPE tissue.
View productFilters
Sort and filter
Sort by
Filters
Related content
NGS-based cancer sequencing methods provide more information in less time compared to single-gene and array-based approaches.
Our sequencing and microarray technologies support a broad range of cancer genomics research applications, from DNA to RNA analysis, epigenetics, and more.
With targeted resequencing, a subset of genes or a genomic region is isolated and sequenced, which can conserve lab resources.